SEARCH:   Advanced

Blood, 1 March 2006, Vol. 107, No. 5, pp. 2098-2100. Prepublished online as a Blood First Edition Paper on November 17, 2005; DOI 10.1182/blood-2005-08-3395. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-08-3395v1 107/5/2098    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Campbell, P. J. Articles by Reilly, J. T. Search for Related Content PubMed PubMed Citation Articles by Campbell, P. J. Articles by Reilly, J. T. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis Peter J. Campbell, Martin Griesshammer, Konstanze Döhner, Hartmut Döhner, Rajko Kusec, Hans C. Hasselbalch, Thomas Stauffer Larsen, Niels Pallisgaard, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès, Christophe Desterke, Bernadette Guerton, Brigitte Dupriez, Dominique Bordessoule, Pierre Fenaux, Jean-Jacques Kiladjian, Jean-François Viallard, Jean Brière, Claire N. Harrison, Anthony R. Green, and John T. Reilly From the Department of Haematology, University of Cambridge, United Kingdom; the Department of Internal Medicine III, University of Ulm, Germany; the Department of Haematology and Clinical Chemistry, Merkur University Hospital, Zagreb, Croatia; the Department of Haematology and Pathology, Odense University Hospital, Denmark; the Institut National de la Santé etdela Recherche Médicale (INSERM) U362, Villejuif, and Laboratoire d'Hématologie, Henri Mondor Hospital, Créteil; INSERM U602, Villejuif, France; the Hématologie Clinique, Centre Hospitalier de Lens; the Hématologie Clinique, Center Hospitalier Régional Universitaire (CHRU) Limoges; the Hématologie Clinique, Hôpital Avicenne, Bobigny; the Hôpital du Haut-Lévêque, Pessac; the Department of Hematology, Hôpital Beaujon, Clichy, France; the Department of Haematology, St Thomas's Hospital, London, United Kingdom; and the Department of Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom. Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)–based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. V. Jones, N. C.P. Cross, H. E. White, A. R. Green, and L. M. Scott Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis Haematologica, October 1, 2008; 93(10): 1560 - 1564. [Abstract] [Full Text] [PDF] P. A. Beer, P. J. Campbell, L. M. Scott, A. J. Bench, W. N. Erber, D. Bareford, B. S. Wilkins, J. T. Reilly, H. C. Hasselbalch, R. Bowman, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood, July 1, 2008; 112(1): 141 - 149. [Abstract] [Full Text] [PDF] A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica, January 1, 2008; 93(1): 34 - 40. [Abstract] [Full Text] [PDF] E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF] J. W. Vardiman Integration of Histology and Genetics in the Diagnosis and Classification of Myeloproliferative Neoplasms ASCO Educational Book, January 1, 2008; 2008(1): 339 - 345. [Abstract] [Full Text] [PDF] A. Tefferi Management of Myeloproliferative Neoplasms and the Promise of Targeted Therapy ASCO Educational Book, January 1, 2008; 2008(1): 346 - 348. [Abstract] [Full Text] [PDF] B. S. Wilkins, W. N. Erber, D. Bareford, G. Buck, K. Wheatley, C. L. East, B. Paul, C. N. Harrison, A. R. Green, and P. J. Campbell Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes Blood, January 1, 2008; 111(1): 60 - 70. [Abstract] [Full Text] [PDF] G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, M. Massa, V. Rosti, R. Campanelli, L. Villani, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis Blood, December 1, 2007; 110(12): 4030 - 4036. [Abstract] [Full Text] [PDF] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF] Q. Chen, P. Lu, A. V. Jones, N. C.P. Cross, R. T. Silver, and Y. L. Wang Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders J. Mol. Diagn., April 1, 2007; 9(2): 272 - 276. [Abstract] [Full Text] [PDF] R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood, November 15, 2006; 108(10): 3548 - 3555. [Abstract] [Full Text] [PDF] A. Tefferi Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Hematology, January 1, 2006; 2006(1): 240 - 245. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020